Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences is attractive fundamentally because its SGT-003 DMD program appears meaningfully differentiated on safety and delivery, with 53 patients dosed and no reported drug-induced liver injury to date, while also showing consistent microdystrophin, nNOS, and cardiac biomarker signals that could support functional benefit. The company’s regulatory backdrop is improving as FDA leadership looks more constructive toward rare-disease gene therapy, making the late-4Q26 meeting and YE-26/early-27 functional readout especially important de-risking events. Beyond DMD, optionality in FA and CPVT adds pipeline value to a stock trading around ~$700m EV versus a DMD market described as potentially $1b+ on conservative assumptions, leaving room for significant re-rating if data hold.

Solid Biosciences is a clinical-stage gene therapy company whose outlook is weakened by the sector’s well-known execution and safety risks, especially because AAV programs have historically stumbled on hepatotoxicity and immune-mediated adverse events. Although its biomarker trends are encouraging, the broader DMD field was shaken by March and June 2025 severe acute liver failure cases in ELEVIDYS, and FDA restrictions to ambulatory patients underscore how quickly regulatory access can contract when safety concerns emerge. The investment case is further constrained by commercialization and financing risk, as Solid reported about $236 million in cash, cash equivalents, investments, and available-for-sale securities as of September 30, 2025, while future development and launch efforts may require additional partnerships or dilution.